SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s rises on inking pact with Cutis Pharma for API, drug research

08 Apr 2016 Evaluate

Dr. Reddys Laboratories is currently trading at Rs 3061.00, up by 29.60 points or 0.98% from its previous closing of Rs. 3031.40 on the BSE.

The scrip opened at Rs. 3060.00 and has touched a high and low of Rs 3085.00 and Rs 3050.00 respectively. So far 12476 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 4382.95 on 20-Oct-2015 and a 52 week low of Rs 2750.00 on 21-Jan-2016.

Last one week high and low of the scrip stood at Rs 3073.00 and Rs 2966.00 respectively. The current market cap of the company is Rs 52205.94 crore.

The promoters holding in the company stood at 25.57% while Institutions and Non-Institutions held 43.50% and 30.93% respectively.

Dr. Reddy’s Laboratories has entered into active pharmaceutical ingredient (API) supply and joint development agreements with the US-based Cutis Pharma to advance several programs in Cutis Pharma’s R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.

This partnership has significant strategic benefits for both the entities. Dr Reddy’s breadth of expertise and international infrastructure provide great synergy to Cutis Pharma’s own R&D and commercial organisations and will be a significant catalyst in its plans to fast-track the development of three of its programs towards new drug application (NDA) filings.

Cutis Pharma is a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, while Dr. Reddy's Laboratories, is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1293.25 -13.55 (-1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×